Skip to content
Sunday, November 15, 2026
London Fortune Solutions

Zimbabwe Rejects ‘One-Sided’ US Health Aid Deal Due to Data Fears

Medical funding image
The proposed American financial assistance would have supported initiatives for treating and preventing HIV/Aids, TB, and malaria.

Zimbabwe has declined a major American healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years over the United States' demand for confidential information.

This rejection became public after a internal memorandum from December was disclosed, which showed President Emmerson Mnangagwa believed the agreement was "skewed".

A government representative later clarified that the United States was requesting health data for scientific study and profit while was unwilling to guarantee the benefits from any future vaccines.

"We are forced to start the challenging and unfortunate task of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.

Her embassy indicated the US had provided over $1.9bn in health funding to Zimbabwe over the last two decades.

A doctors' association in Zimbabwe has called for more talks to find a agreement acceptable to all parties so the nation's critical HIV treatment initiative can proceed.

Wider Background

This rejection follows a comparable situation in neighbouring Kenya, where a court blocked a similar deal with the US after legal challenges were raised about the security of citizens' medical information.

Since resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).

The agency had managed aid for the American government, but Trump argued its spending was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and accountability.

Based on reports, 16 nations in Africa have so far agreed to these new agreements, representing more than $18.3bn in committed funds.

Details of the Declined Agreement

This assistance for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.

"It is our view this collaboration might have yielded extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on HIV treatment through American-funded programmes," the Ambassador said.

However, official spokesman Nick Mangwana argued the arrangement was "unfair".

"The proposal required Zimbabwe to provide its biological resources and data indefinitely, with no equivalent assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," he stated.

"Effectively, our country would supply the raw materials for scientific discovery with no assurance that the end products would be available to our people if a future disease outbreak emerge."

National Interest and International Frameworks

Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were upending systems previously established via the international health agency.

The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with potential pandemics.

"This framework is designed to ensure that when a country contributes its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to create them."

Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," Mangwana stressed.

"We are open to continued discussions with our American counterparts on how future collaboration might be structured in a way that honours the independence and interests of each country."

Medical Community Reaction

Medical experts expressed it understood the official position, but suggested that talks need to persist since much of the nation's Aids initiatives were funded by international support.

"If technical issues arise, including those involving data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it said.

This impasse highlights the ongoing debate between accepting vital international aid and protecting national sovereignty in an ever more data-driven world.

JC
Written by

John Cain

Elena Hartwell is a seasoned financial strategist with over a decade of experience in wealth management and investment planning.

London Fortune Solutions

Type to search articles.